Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNT1 | O60563 | 17/20 | 0.62 |
| ▸ | CDK9 | P50750 | 4/20 | 0.53 |
| ▸ | CCNK | O75909 | 1/20 | 0.53 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9950015 | 0.91 | CCNT1 (0.66) | CCNT1CDK9CCNK | |
| SCHEMBL9949411 | 0.91 | CCNT1 (0.66) | CCNT1CDK9CCNK | |
| SCHEMBL9949247 | 0.91 | CCNT1 (0.66) | CCNT1CDK9CCNK | |
| SCHEMBL1947126 | 0.89 | CCNT1 (0.62) | CCNT1CDK9CCNK | |
| SCHEMBL1948792 | 0.89 | CCNT1 (0.62) | CCNT1CDK9CCNK | |
| SCHEMBL1947792 | 0.88 | CCNT1 (0.70) | CCNT1CDK9HDAC3HDAC1HDAC6 | |
| SCHEMBL1948656 | 0.87 | CCNT1 (0.62) | CCNT1CDK9CCNKHDAC3HDAC1 | |
| SCHEMBL1462984 | 0.87 | CCNT1 (0.62) | CCNT1CDK9CCNKHDAC3HDAC1 | |
| SCHEMBL1463013 | 0.87 | CCNT1 (0.62) | CCNT1CDK9CCNKHDAC3HDAC1 | |
| SCHEMBL1945582 | 0.86 | CCNT1 (0.68) | CCNT1CDK9HDAC3HDAC1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120165306-A1 | PYRAZINYLPYRIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2012-06-28 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165306-A1 | PYRAZINYLPYRIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | CDK4, CDK1, CCNI | CCNT1 39/4885CDK9 16/4885CCNK 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.